US EditionTrial Shows Mavacamten Benefits Adolescents with Obstructive Heart Condition
Camzyos significantly reduced heart obstruction in 44 adolescents with obstructive hypertrophic cardiomyopathy, showing improvements in cardiac structure and symptoms with a safety profile similar to placebo.
- On Sunday, March 29, Bristol Myers Squibb announced positive Phase 3 SCOUT-HCM trial results for Camzyos, the first cardiac myosin inhibitor tested in adolescents aged 12 to 17 years with obstructive hypertrophic cardiomyopathy .
- Pediatric patients with oHCM face significant side effects or invasive risks from current therapies, according to Joseph Rossano, chief of cardiology at Children's Hospital of Philadelphia .
- In the 44-patient trial, mavacamten reduced the Valsalva left ventricular outflow tract gradient by 48.5 mm Hg versus 0.5 mm Hg for placebo over 28 weeks, with no new safety signals identified.
- Beyond symptom relief, Rossano noted the drug showed signs of "favorably remodeling the heart," potentially altering disease progression and offering a targeted option for pediatric patients lacking approved therapies.
- BMS plans to present 56-week data at an upcoming congress, while researchers explore investigating efficacy in children younger than 12 and continue long-term monitoring to confirm findings.
26 Articles
26 Articles
Mavacamten improves obstruction in adolescents with hypertrophic cardiomyopathy
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26). The trial is the first to test mavacamten in patients you…
Trial shows mavacamten benefits adolescents with obstructive heart condition
Adolescent patients with obstructive hypertrophic cardiomyopathy (HCM) who received the drug mavacamten saw a significant improvement in left ventricular outflow tract (LVOT) gradient, a measure of blood flow obstruction in the heart, compared with those who received a placebo, according to a small study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).
Mavacamten shows benefit for adolescents with obstructive hypertrophic cardiomyopathy
NEW ORLEANS — New data support the use of mavacamten as a treatment option for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, researchers reported at the American College of Cardiology Scientific Session.The SCOUT-HCM trial is the first to evaluate mavacamten (Camzyos, Bristol Myers Squibb) in adolescents. Mavacamten, a cardiac myosin inhibitor, is currently FDA
Coverage Details
Bias Distribution
- 61% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
